Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs
Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs
This study was a multicentre, double-blind, randomised, placebo-controlled parallel group study consisting of 4 visits over a period of 6 months. The primary variable was to assess theefficacy of esomeprazole 40 mg orally qd (E40) or esomeprazole 20 mg orally qd (E20) versus placebo orally qd after 6 months of treatment for the prevention of relapse of upper GI symptoms associated with NSAID use, including COX-2 selective NSAIDs, in patients receiving daily NSAID therapy.
Inclusion Criteria:
Exclusion Criteria:
Various Cities, New South Wales, Australia
Various Cities, South Australia, Australia
Various Cities, Tasmania, Australia
Various Cities, Victoria, Australia
Hlu¿Ãn, Czechia
Ostrava - T¿ebovice, Czechia
Bærum Postterminal, Norway
Bia¿ystok, Poland
Wrze¿nia, Poland
Pie¿¿any, Slovakia
Bradford Upon Avon, United Kingdom